argenx Reports Third Quarter 2025 Financial Results and Provides Business Update

$1.13 billion in third quarter global product net sales 

On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic

Read more at globenewswire.com